Polypeptide Antagonist for NASH and HCC Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating and diagnosing non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) are limited, with few effective treatment options and a lack of reliable early detection markers, leading to high recurrence rates and increasing global health challenges.
Innovation Solution
Administration of a polypeptide antagonist targeting the Na/K-ATPase/Src receptor complex, specifically using sequences like SEQ ID NO: 1 or functional fragments, to disrupt signaling pathways, and using biomarkers such as Caveolin-1, Survivin, and SMAC for diagnosis and prognosis through methods including mass spectrometry and immunoassay analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatment methods are used for NASH and HCC, then current standard of care is maintained, but treatment effectiveness is limited and recurrence rates remain high
Solution Approach 1:
The patent introduces a polypeptide antagonist as an intermediary substance that specifically binds to and blocks the Na/K-ATPase/Src receptor complex. This mediator disrupts the abnormal signaling pathway involved in NASH and HCC pathogenesis, providing a novel mechanism of action that is not covered by conventional treatments. The antagonist serves as a bridge between the therapeutic goal and the molecular target, enabling precise intervention in the disease process.
Solution Approach 2:
The patent targets a specific molecular parameter - the Na/K-ATPase/Src receptor complex signaling activity - which is dysregulated in NASH and HCC. By measuring and modulating this specific parameter using the polypeptide antagonist, the treatment addresses the underlying molecular pathology rather than just symptoms. This parameter-based approach allows for personalized treatment strategies based on individual patient molecular profiles.
2Loss of time
If early detection markers are not available, then diagnosis occurs at later stages, but disease progression continues unchecked with higher mortality
Solution Approach 1:
The patent extracts and utilizes specific biomarkers (Caveolin-1, Survivin, SMAC) from biological samples to serve as early detection indicators. By isolating and measuring these specific molecular components, the method enables early diagnosis before significant clinical symptoms develop. The extraction of these markers from complex biological matrices allows for their quantification and use as diagnostic tools.
Solution Approach 2:
The patent replaces traditional mechanical or physical diagnostic methods with molecular-based detection using mass spectrometry and immunoassays. Instead of relying on physical examinations or imaging alone, the diagnosis is substituted with precise molecular measurement of biomarker levels, enabling earlier and more accurate detection of NASH and HCC.
3Reliability
If only weight loss and exercise are used to treat NASH, then some progression is reduced, but additional effective treatment methods are needed
Solution Approach 1:
The polypeptide antagonist serves as a pharmacological mediator that complements lifestyle interventions. While weight loss and exercise address metabolic factors, the antagonist directly targets the molecular signaling pathway (Na/K-ATPase/Src complex) involved in disease progression. This intermediary provides a bridge between lifestyle modifications and molecular-level disease control, offering a more comprehensive treatment approach.
Data Source
AI summary
Methods for treating non-alcoholic steatohepatitis and/or hepatocellular carcinoma include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Methods and assays for diagnosis or prognosis of non-alcoholic steatohepatitis and/or hepatocellular carcinoma in a subject are also provided and include the steps of providing a biological sample from the subject, determining an expression level or activity in the sample of at least one biomarker selected from Caveolin-1, Survivin, and SMAC; and comparing the expression level or activity of the at least one biomarker in the sample, if present, to a control expression level or activity of the at least one biomarker. Prophylaxis or treatment of the non-alcoholic steatohepatitis and/or hepatocellular carcinoma in a subject can then be initiated based on the expression level or activity of Caveolin-1, Survivin, and SMAC in the sample.